- Home
- SPRO vs TEAF Comparison
SPRO vs TEAF Comparison
Compare SPRO & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- TEAF
- Stock Information
- Founded
- SPRO 2013
- TEAF 2017
- Country
- SPRO United States
- TEAF United States
- Employees
- SPRO N/A
- TEAF N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- SPRO Health Care
- TEAF Finance
- Exchange
- SPRO Nasdaq
- TEAF Nasdaq
- Market Cap
- SPRO 162.1M
- TEAF 163.0M
- IPO Year
- SPRO 2017
- TEAF N/A
- Fundamental
- Price
- SPRO $2.18
- TEAF $12.17
- Analyst Decision
- SPRO Buy
- TEAF
- Analyst Count
- SPRO 4
- TEAF 0
- Target Price
- SPRO $5.00
- TEAF N/A
- AVG Volume (30 Days)
- SPRO 784.3K
- TEAF 56.1K
- Earning Date
- SPRO 08-12-2025
- TEAF 01-01-0001
- Dividend Yield
- SPRO N/A
- TEAF 9.20%
- EPS Growth
- SPRO N/A
- TEAF N/A
- EPS
- SPRO N/A
- TEAF N/A
- Revenue
- SPRO $44,584,000.00
- TEAF N/A
- Revenue This Year
- SPRO N/A
- TEAF N/A
- Revenue Next Year
- SPRO N/A
- TEAF N/A
- P/E Ratio
- SPRO N/A
- TEAF N/A
- Revenue Growth
- SPRO N/A
- TEAF N/A
- 52 Week Low
- SPRO $0.51
- TEAF $11.11
- 52 Week High
- SPRO $3.22
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- SPRO 32.49
- TEAF 56.06
- Support Level
- SPRO $2.30
- TEAF $12.05
- Resistance Level
- SPRO $2.45
- TEAF $12.18
- Average True Range (ATR)
- SPRO 0.11
- TEAF 0.10
- MACD
- SPRO -0.07
- TEAF -0.02
- Stochastic Oscillator
- SPRO 2.03
- TEAF 54.30
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a USA-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.